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Mutations in the X-linked gene doublecortin lead to “double cortex” syndrome (DC) in females and to X-linked
lissencephaly (XLIS) in males. Because most patients with DC and XLIS are sporadic, representing de novo double-
cortin mutations, we considered that some of these patients could be somatic or germline mosaics. Among a
population of 20 patients and their families, we found evidence for mosaic doublecortin mutations in 6 individuals.
Germline mosaicism was identified in two unaffected women, each with two affected children. Additionally, one
affected male with DC was found to be a somatic mosaic, which presumably spared him from the more severe
phenotype of lissencephaly. The high rate of mosaicism indicates that there may be a significant recurrence risk for
DC/XLIS in families at risk, even when the mother is unaffected.
Introduction
Double cortex (DC [MIM 600348 and MIM 300067])
and X-linked lissencephaly syndrome (XLIS [MIM
300067]) is an X-linked dominant disorder in which
mothers with DC transmit DC to their daughters and
XLIS to their sons (Pinard et al. 1994). Mutations in
doublecortin (DCX) account for the majority of cases
(des Portes et al. 1998a, 1998b; Gleeson et al. 1998;
1999b). In XLIS, cortical neuronal migration is severely
disrupted, leading to a rudimentary four-layered cortex
(Berg et al. 1998). In DC, one population of neurons
forms a relatively normal cortex whereas a second pop-
ulation apparently arrests during migration, leading to
a collection of neurons beneath the cortex. Because of
lyonization, affected females with a DCX mutation are
mosaics for two populations of neurons, which presum-
ably segregate according to which of the copies of DCX
is active. Because DC is seen with heterozygous DCX
mutations and is a less severe phenotype than lissenceph-
aly, DC is considered, on the basis of lyonization, to be
a mosaic phenotype.
In families with a single affected child with DC/XLIS
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that are considering having other children, the risk of
recurrence in future children is unclear. It previously had
been suggested that, in the setting of a single affected
girl with DC or a single boy with XLIS, the mother
should have magnetic-resonance imaging (MRI) of the
brain, to determine whether she is subtly affected and
therefore likely to carry the DCX mutation (Clark and
Noebels 1999). If evidence of DC is detected by the
brain MRI, then the mother likely carries theDCXmu-
tation, and her future children would have a 50%
chance of inheriting it. Because a male with a DCX
mutation should be clinically affected, brain MRI typ-
ically is not performed on the father. Of course, these
recommendations do not consider either the possibility
that either parent carries the mutation but is clinically
unaffected or the possibility that either parent is an un-
affected somatic or germline mosaic for the mutation,
each of which is associated with up to a 50% incidence
of recurrence of DC or XLIS in future children.
Two families that have unaffected parents and a sib
pair in which one child has DC and the other has XLIS
have been identified, indicating that the mother in each
of these families transmitted the mutation to two off-
spring. The most likely explanations for the finding that
these mothers were unaffected are that they either (1)
had skewed X inactivation or (2) were germline or so-
matic mosaics for the DCX mutation. We investigated
both of these possibilities in each of these individuals,
and we present data suggesting that the mother in each
family carries a germline DCX mosaic mutation, which
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presumably spares them from displaying clinical fea-
tures of DC.
On the basis of these results, we searched for the
possibility of mutation mosaicism in settings in which
it was likely to occur. We searched for evidence of (a)
somatic mosaicism among patients with DC, (b) somat-
ic or germline mosaicism among unaffected parents of
patients with DC, and (c) somatic mosaicism among the
few males identified as being affected with DC. We re-
port that mutation mosaicism was identified in each of
these settings, suggesting that germline- and somatic-
mutation mosaicism is not uncommon among patients
with DCX mutations and that the recurrence risk in
families with a single affected child with DC/XLIS may
be significant.
Patients and Methods
Patients
Two families displaying non-Mendelian inheritance
(i.e., two affected children with DC/XLIS whowere from
unaffected parents) were included in this study. For one
of these families, the mutation has been reported else-
where (Gleeson et al. 1999b). Six females with sporadic
DC from whom parental DNA was available (mutations
for which had been reported elsewhere [Gleeson et al.
1999b]) were included in this study, to allow a search
for mutation mosaicism among unaffected parents of
patients with DC. Ten additional females with sporadic
DC from whom parental DNA was not available also
were included, to allow a search for mutation mosaicism
among patients affected with DC. Additionally, two
males with sporadic DC who had not previously been
evaluated for a DCX mutation were included in this
study. Family or patient identification numbers frompre-
vious publications have been retained (Gleeson et al.
1998, 1999b). A brain MRI was performed on all clin-
ically affected individuals, as well as on mothers with
either somatic or germline mosaicism, to determine af-
fection status.
Mutation Analysis
This research was approved by the Human Subjects
Committees at Children’s Hospital (Boston), Beth Israel
Deaconess Medical Center, the University of Minnesota,
and the University of California, San Diego. Genomic
DNAwas extracted from lymphocytes, as described else-
where (Gleeson et al. 1998). Each exon was amplified
by PCR and was analyzed for single-stranded confor-
mational polymorphism (SSCP), on a nondenaturing
polyacrylamide gel. To increase the sensitivity of mu-
tation detection, each exon was also analyzed on an
MDE (mutation-detection enhancement) gel, according
to the recommendations of the manufacturer (FMC
BioProducts). Bands were visualized by silver staining
according to the manufacturer’s directions (Promega).
Polymorphic bands were excised from the gel, reampli-
fied by PCR, and sequenced in both directions, to iden-
tify mutations, described elsewhere (Gleeson et al. 1998).
The DNA from the unaffected parents of each patient
with sporadic DC also was analyzed by SSCP and was
run in a lane next to that containing the patient’s DNA,
to test whether the mutation derived from somatic mo-
saicism in one of the parents. Somatic mosaicism was
identified by the presence, on an SSCP gel, of mutant
bands at an intensity lower than that of the wild-type
bands.
Band intensity was quantitated by three methods.
First, each genomic PCR reaction was repeated in the
presence of 1 mCi of a[P32]-dCTP per reaction, over three
different cycle numbers (25, 30, and 35 cycles), to ensure
that the amplification was in the linear range, followed
by SSCP analysis of PCR products and exposure to a
Phosphoimager cassette (Molecular Dynamics) for 2–3
d. Band intensity was quantitated by GENEQUANT
software (Molecular Dynamics). Second, each genomic
PCR reaction was repeated, without radioactivity, and
was analyzed by SSCP, visualized by silver staining,
photographed at several varying exposure times, to en-
sure that the bands were not saturated, and digitized by
computer scanning, and then band intensity was quan-
titated by GENEQUANT software. Using this method,
we could determine mosaicism at a level as low as 5%,
as determined by mixture of known amounts of wild-
type and mutant alleles. Third, each genomic PCR re-
action was repeated and directly sequenced by Big Dye
(ABI) dye terminators and an ABI 377 or 310 sequencer.
After automated sequence analysis, the area under the
curve at the site of the mutation mosaicism was esti-
mated, to ensure that it was consistent with results from
the two previously described methods of quantification.
Because the peaks from fluorescent sequencing are not
quantitative, the area under the curve was not measured.
To be certain that preferential amplification of the
wild-type allele versus the mutant allele did not account
for the allele intensity differences, the two alleles were
excised from the SSCP gel, diluted to equimolar con-
centrations, and reamplified over 20, 25, and 30 cycles,
and the intensity was reanalyzed by SSCP and band
quantification. Additionally, PCR products derived from
amplification of patients’ DNA were cloned to separate
the two alleles, by polishing the ends with T4 DNA
polymerase, followed by cloning with ZeroBlunt cloning
vector (Invitrogen). A clone representing the wild-type
and the mutant alleles was identified for each mutation,
by direct sequencing of several clones from each patient.
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Figure 1 Germline DCX mutation mosaicism in unaffected par-
ents of two affected children. In both families, an unaffected mother
has a girl with DC (half-blackened circle) and a boy with XLIS (black-
ened square), and the maternal genotype appears to be normal. SSCP
gel analysis of both families demonstrates two normal bands in each
parent (black arrows), two mutant bands from males with lissenceph-
aly (gray arrows), and four bands (reflecting a normal allele and a
mutant allele) from females with DC. In family I, other faint bands
are visible in individuals II-1 and I-2, likely representing either false
priming or minor conformers of the PCR product.
PCR with 0.1 ng of miniprep DNA and the same pair
of primers, over 20 or 25 cycles, was performed in the
presence of 1 mCi of a[P32]-dCTP, and the band intensity
was quantitated by Phosphoimager analysis.
Results
Mosaicism Detection
All patients and their parents were analyzed for mo-
saicism, by PCR of the DCX coding region. In patients
with a previously identified mutation, only the mutant
exon was reanalyzed. The percentage of mosaicism was
determined by three independent methods, the results of
which which, for any given patient, were quantitatively
within 5% of one another. The results reported in table
1 are from the first method. Germline mosaicism was
inferred on the basis of the absence of a DCX mutation
in peripheral blood lymphocytes in an obligate carrier
(Zlotogora 1998). Family I displayed an A400T point
mutation, leading to a premature stop codon at amino
acid position 134. Male 1 with sporadic DC displayed
a G628T point mutation, leading to a V210F amino acid
substitution. All mutations and a summary of mutation-
mosaicism findings are presented in table 1.
Germline DCX Mutation Mosaicism in Unaffected
Parents of Two Children
In families H and I, the unaffected parents had two
children with DC/XLIS, consistent with either maternal
germline or somatic mosaicism. Both families have de-
monstrable DCX mutations in both affected children.
Since the father did not transmit an X chromosome to
his son, each mother must carry the DCX mutation in
her germline. However, the maternal genotype of lym-
phocytes in both families is normal on the basis of SSCP
analysis, suggesting that each mother is a germline mo-
saic for theDCXmutation (fig. 1). We could not exclude
the possibility (1) that either unaffected mother carries
a subtle somatic mutation at levels that, in peripheral
blood lymphocytes, are too low to be detected by SSCP
or (2) that, in additional areas, which are not reflected
in lymphocyte-based PCR analysis, either unaffected
mother is a somatic mosaic.
Somatic DCX–Mutation Mosaicism in the Unaffected
Parents of a Patient with Sporadic DC
On the basis of these results, we considered that some
unaffected parents of patients with sporadic DC might
carry a somaticDCXmutation, so we tested for somatic
mosaicism in each of the parents of our cohort of six
patients with sporadic DC from whom DNA was avail-
able. The unaffected mother of DC patient 7 showed
evidence of somatic mosaicism, in peripheral blood lym-
phocytes, of ∼22% (fig. 2A), whereas, on the basis of
SSCP analysis, both parents from each of the other fam-
ilies had a normal genotype. Direct sequencing of the
genomic PCR product showed the wild-type sequence
and the frameshift mutation, with the mutation repre-
sented at a level below that of the wild-type, supporting
the SSCP-based finding of mosaicism (fig. 2B). To be
certain that the difference in intensity between the wild-
type and mutant allele was not the result of selective
PCR amplification of the wild-type allele, the two alleles
were separated by SSCP and cloning and were individ-
ually reamplified by use of the same primer pair. Selective
amplification of one allele over the other was not de-
tected by either method (data not shown), suggesting
that the difference, in band intensity, that genomic PCR
detected between the wild-type and the mutant allele is
the result of mosaicism.
Because DC can have a very subtle phenotype (Pinard
et al. 1994), we questioned whether the mother of pa-
tient 7 could be a very subtly affected somatic mosaic.
Thus, she was studied by brain MRI, currently the most
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Figure 2 Somatic DCX–mutation mosaicism in the unaffected
parents of an affected child. An unaffected mother has a daughter with
DC (half-blackened circle). As is shown in panel A, this mother (I-1)
was found to carry the same DCX mutation as was seen in her daugh-
ter, but the mutant band (rightward-pointing gray arrowheads) is of
lower intensity than the normal band (rightward-pointing black ar-
rowheads) (i.e., 22% of the intensity of the wild-type band), suggesting
that the mother is a somatic mosaic for theDCXmutation. Themother
has normal intelligence and the results of a brain MRI were normal,
suggesting that she is clinically and subclinically unaffected. As is
shown in panel B, the somatic DCX mutation is also visible on the
basis of direct sequencing of genomic DNA in I-1 compared with that
in a normal control. In I-1 sequence, the mutant sequence is seen as
lower-height peaks that underlie the normal peaks. Because the mu-
tation in I-1 is a CT deletion, the lower-height peaks in this figure are
the bases AC, which are indicated by two downward-pointing gray
arrows.
Figure 3 Somatic DCX–mutation mosaicism in affected females
with sporadic DC (half-blackened circles). These two females with
DC—Sporadic 64 (II-1) and Sporadic 17 (II-1)—have de novo DCX
mutations (rightward-pointing gray arrowheads) that are, respectively,
31% and 43% of the intensity of the wild-type band (rightward-point-
ing black arrowheads), suggesting that they are somatic mosaics for
the DCX mutation. The somatic DCX mutations are also visible on
the basis of direct sequencing of genomic DNA in both patients, com-
pared with that in a normal control. For Sporadic 64, the mutant
sequence is seen as lower-height peaks that underlie the normal peaks.
Because the mutation in Sporadic 64 is a CT deletion, the lower-height
peaks in this figure are the bases GGA, which are indicated by three
downward-pointing gray arrows. For Sporadic 17, the lower-height
peaks are the bases CA, which are indicated by two downward-point-
ing gray arrows. The sequence for Sporadic 17 was obtained with the
reverse primer, and thus the A deletion is seen as a T deletion, with
a resultant leftward shift of the bases of the mutant allele. Because of
an artifact of the ABI 310 sequencer, the mutant A peak, which is
indicated by the second downward-pointing gray arrow, is shifted
slightly leftward relative to the wild-type C peak.
sensitive test for DC. The results of her brain MRI were
normal, and she has normal intelligence and no history
of seizures, making it very unlikely that she is affected
clinically or subclinically. Therefore, her somatic DCX
mutation may have arisen during development, after ec-
toderm (brain) differentiated from mesoderm (lympho-
cyte and germ cells). Another possibility is that the mu-
tation is present in all three of her somatic cell lines but
that, because favorable X inactivation hinders expres-
sion of the mutantDCX in her nervous system, she does
not display DC. X-inactivation studies using lympho-
cyte-derived DNA from this individual do not show sig-
nificantly skewed X inactivation (data not shown), but
this finding does not fully exclude this possibility. Anal-
ysis of skin-biopsy results could help to distinguish be-
tween these two possibilities, but this procedure was not
performed in this study.
Somatic DCX–Mutation Mosaicism in Affected Females
with Sporadic DC
On the basis of these results, we considered that some
of the patients with sporadic DC and previously iden-
tified mutations might, in fact, carry a somatic DCX
mutation, rather than a germline mutation. Therefore,
we analyzed our cohort of 16 females with sporadic DC,
to investigate this possibility. Two of the 16 females with
sporadic DC showed evidence of somatic mutations, in-
volving either 31% or 43%of lymphocyte (somatic) cells
(fig. 3A and B). Direct sequencing of the genomic PCR
product from patient 64 with sporadic DC showed the
wild-type sequence and the frameshift mutation, with
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Figure 4 SomaticDCX–mutation mosaicism in an affected male
with sporadic DC (half-blackened square). As is shown in panel A,
this male was found to carry a de novo DCX mutation allele (right-
ward-pointing gray arrowhead) and a wild-type DCX allele (right-
ward-pointing black arrowheads). Males should have just one DCX
allele, suggesting that this male is a somatic mosaic for the DCX
mutation. As is shown in panel B, the somatic DCX mutation is also
visible on the basis of direct sequencing of genomic DNA in male 1
with sporadic DC (i.e., II-1), compared with that in a normal control.
The mutant sequence is shown as a lower-height T peak that underlies
the normal G peak, which is indicated by the downward-pointing gray
arrow.
the mutation represented at a level below that of the
wild-type, supporting the SSCP-based finding of mosa-
icism (fig. 3A). Again, mutant and wild-type alleles were
separated and were individually reamplified; and no se-
lective amplification of one allele over the other was
detected (data not shown), supporting the finding of mu-
tation mosaicism in these patients. The unaffected par-
ents do not show, on the basis of SSCP, evidence of the
mutation, suggesting that the mutation arose sometime
during embryogenesis of the affected patient. The phe-
notype of one of these patients (patient 17) is clinically
indistinguishable from that of other females with spo-
radic DC (Gleeson et al. 2000), and the phenotype of
the other mosaic patient with sporadic DC is also typical
of DC (W.B.D. and M.E.R., unpublished data), sug-
gesting that patients with somatic DCX mutations are
at risk for the full clinical severity of disease.
Somatic DCX Mutation–Mosaicism in an Affected
Male with Sporadic DC
We considered the possibility that males with DC
could display somatic DCX mutations, as an explana-
tion for why these males display the heterozygous (fe-
male) phenotype, as opposed to the more typical hemizy-
gous (male) phenotype, of lissencephaly. In our cohort
of patients with DC, there were two males with sporadic
DC on whom DCX mutation analysis was performed
for this study. One of these males (male 1) displayed a
de novo G628T DCX mutation, predicted to lead to a
V210F amino acid substitution. This male displayed two
alleles for this exon (fig. 4A), raising the possibility that
he either has a duplication of part or all of the X chro-
mosome or carries a somatic DCX mutation. We used
karyotype analysis to investigate the possibility of an
XXY genotype, and we used Southern blot analysis with
a full-length DCX probe to search for a duplication;
results of both analyses were normal (data not shown).
On the basis of SSCP analysis, the intensity of themutant
band was ∼31% of that of the wild-type band, sug-
gesting that the majority of the patient’s cells have the
wild-type DCX allele. Direct sequencing of the genomic
PCR product showed the wild-type sequence and the
base-substitution mutation, with the mutation repre-
sented at a level below that of the wild-type sequence,
supporting the SSCP-based finding of mosaicism (fig.
4B). Again, mutant and wild-type alleles were separated
and individually reamplified; and no selective amplifi-
cation of one allele over the other was detected (data
not shown), supporting the finding of mutation mosai-
cism in this patient. Therefore, this male most likely has
in DCX a somatic mutation leading to a mosaic state
and, because of his mosaic mutation, is spared from the
more severe phenotype of lissencephaly.
Discussion
We demonstrate that germline and somatic mosaicism
for DCX mutations is not infrequent and may take one
of many presentations. Germline mosaicism for DCX
was identified in two unaffected mothers who trans-
mitted the mutation to two of their children. Somatic
mosaicism for DCX was identified in an unaffected
mother who transmitted the mutation to her child, in
two affected females with sporadic DC, and in one male
who displayed the female phenotype. These results fur-
ther support the hypothesis that the DC phenotype re-
sults from a mosaic state in which some neurons express
a normal copy of DCX and some neurons express a
mutant copy of DCX. The mosaic state in a female with
DC is typically a result of X inactivation, but other forms
of mosaicism can produce the same mosaic state. These
results are based on analysis of lymphocyte-derived
DNA and will need to be verified by use of tissue derived
from a second source (e.g., by skin biopsy).Nevertheless,
these finding suggest that multiple forms of mosaicism
(X-inactivation mosaicism and somatic mosaicism) may
be present in a single patient with DC.
des Portes et al. (1998a) have reported a family with
two affected daughters and a less severely affected
mother with a likely somatic DCX mutation. In this
family, the mother had a thin frontal band and displayed
mental retardation less severe than that in her two af-
fected daughters, suggesting that her mosaicism may
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have spared her from the more severe phenotype as-
sociated with the germline mutation and displayed by
her daughters. Although our study identified a mother
with a somatic mosaic DCX mutation as well, the
mother in our study, unlike the mother reported by des
Portes et al., was clinically and radiographically unaf-
fected. The band intensity of the wild-type allele and
the mutant allele was not quantitated in the report by
de Portes et al., so it is not possible to correlate their
results with ours, but their data support our finding that
mosaicism among patients with a DCX mutation is not
an infrequent occurrence.
Although DC in males is infrequent, it appears that
both mutations inDCX and mutations in LIS1 can lead
to DC in males. Because neither mutations in DCX nor
mutations in LIS1 were predicted to lead to DC in
males, the genetic etiology of DC in males was a mys-
tery. Pilz et al. (1999) recently described a male with
DC and a de novo LIS1 mutation, as well as two males
with DC and DCX mutations. Because DC apparently
is a mosaic phenotype, it was initially suspected that
perhaps these DC males would display mosaic muta-
tions; however, the data suggested that each of these
mutations was germline in origin. Although the mech-
anism through which these germline LIS1 and DCX
mutations lead to DC is unclear, Pilz et al. suggested
that perhaps the mutations were hypomorphic alleles,
rather than complete null alleles, accounting for the less
severe phenotype of DC rather than lissencephaly. We
could not exclude a similar mechanism in the male with
sporadic DC who is presented here, but our findings
demonstrating a male with a mosaic DCX mutation
who displays the female phenotype fit well with the idea
that DCX may function in a cell-autonomous manner
during neuronal migration (Francis et al. 1999; Gleeson
et al. 1999a).
On the basis of these results, we hypothesize that at
least some patients with focal cortical dysplasia may
have somatic DCX mutations. In a previous study, we
described three individuals with focal subcortical band
heterotopia in whom no DCX mutation could be iden-
tified (Gleeson et al. 2000); we hypothesized that so-
matic mosaicism could underlie the disease in these in-
dividuals. The current findings support the possibility
that focal subcortical heterotopia may be due, at least
in part, to somatic mutations in DCX. It would be in-
teresting to examine cortical resections from a large co-
hort of patients with focal cortical dysplasias, for evi-
dence of mosaicDCXmutations at the site of dysplasia.
In the present study, individuals displaying !30%mo-
saicism were clinically unaffected, whereas individuals
with 130% mosaicism were clinically affected with DC,
suggesting that individuals with a higher mutation load
are more likely to be clinically and radiographically af-
fected. For example, the unaffected mothers in families
I and H and the mother of female 7 with sporadic DC
each display 22% mosaicism for the DCX mutation
and are unaffected, whereas females 17 and 63 with
sporadic DC and male 1 with sporadic DC each display
31% mosaicism for the DCX mutation. The small
number of patients in the present study precludes a
meaningful statistical analysis, and further refinement
of this lower limit required for phenotypic expression
(130% mosaicism) awaits analysis of a larger patient
group. Nevertheless, these data suggest that there may
be a critical percentage of mosaicism in peripheral blood
lymphocytes that is associated with clinical and radio-
graphic features of DC.
Our findings may have bearing on genetic counseling
regarding the risk of recurrence after the first child is
diagnosed with either DC or XLIS. The risk of recur-
rence of either DC or XLIS after the birth of a first
affected child has been believed to be low, especially if
results of brain MRI of the mother are normal (Clark
and Noebels 1999). However, we have presented three
unaffected females with germline or somatic mosaicism
for DCX, each with presumably a 50% chance of re-
currence of the disease in future children. It is not pos-
sible to predict at this time the recurrence risk after the
birth of a single child affected with either DC or XLIS,
but analysis of a larger cohort of patients with sporadic
DC and their parents may help to clarify this issue. Our
experience with a limited cohort suggests that somatic
and germline mosaicism in unaffected mothers with ei-
ther DC or XLIS is seen in ∼10% of cases, a finding
that is in keeping with those for autosomal dominant
disorders such as osteogenesis imperfecta and neurofi-
bromatosis (Hall 1988; Zlotogora 1998). Geneticists
must continue to take the risk of somatic and germline
mosaicism into account when the parents of a patient
with either sporadic DC or XLIS are counseled about
the risk of recurrence (Sippel et al. 1998), and DNA
testing for DCX mutations in this clinical setting may
be helpful. For example, the mother in family I (I-2)
recently became pregnant, and amniocentesis was per-
formed to determine whether the DCX mutation was
present. Fortunately, the fetus did not carry the muta-
tion, and the woman gave birth to a normal child
(I.A.Y., J.G.G., and C.A.W., unpublished data).
Genetic counselors may also need to take these results
into consideration when determining the recurrence risk
for lissencephaly in males, since mutations in either
DCX or the chromosome 17 gene LIS1 (MIM 247200)
lead to nearly indistinguishable phenotypes, although
the inheritance and recurrence risk are very distinct.
LIS1 mutations appear to be exclusively germline, and
the only documented recurrences have been in the set-
ting of a balanced translocation in one parent that be-
came unbalanced on transmission to the affected chil-
dren (Goutieres et al. 1987; Alvarado et al. 1993; Pollin
Gleeson et al.: Mosaic Mutations in doublecortin 581
et al. 1999). Therefore, if a LIS1 mutation is identified
in the absence of a translocation, there is very little risk
of recurrence. However, on the basis of these results, if
a DCX mutation is identified, there appears to be a
significant (up to 10%) risk of recurrence, on the basis
of the possibility of mosaicism in the mother. In the
absence of demonstrable mutations in either gene, the
risk of recurrence is indeterminate. Therefore, mutation
analysis can be very helpful in appropriate situations.
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